The World's Largest Podcast on Fatty Liver Disease

We curate content from our 150+ hour audio library into bite-sized pieces so you can focus on what matters to you.

Get All-Access to all Diabetes registering for a tailored experience. One log-in gives you access to all Diabetes episodes!

S2-1 - Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline

S2-1 – Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline

In the Season 2 debut of the Rising Tide series for healthcare professionals who treat diabetic patients, the patients themselves and their caregivers, co-hosts Ken Cusi and Roger Green are joined by Mazen Noureddin to talk about prevalence and taking action on the frontlines today. The trio explore emerging NASH drugs, noninvasive testing and guidelines for treating different stages of disease progression.

The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide embarks on its second season with new co-host, Ken Cusi, and Roger Green. For the debut, Ken and Roger are joined by hepatologist, researcher and Key Opinion Leader, Mazen Noureddin, to discuss a new chapter of the podcast and why 2023 might be “the best year ever” for Fatty Liver.

05:04
The group considers what made 2022 special. Mazen highlights Madrigal’s positive topline results from the Phase 3 trial of resmetirom for treatment of NASH and liver fibrosis. He also notes Intercept’s study on evaluating the safety and efficacy of obeticholic acid in patients with compensated cirrhosis. Ken underscores the development of algorithms for identifying and diagnosing patients. He is optimistic about different societies aligning to define pathways because NAFLD and NASH are metabolic diseases at the center of converging fields. Roger states his highlight of 2022 to be movement toward noninvasive tests and away from biopsies.

14:26
Conversation expands on the NASH drug pipeline. Mazen cites utility in GLP-1 medications, like semaglutide, and the pan-PPAR agonist, lanifibranor. Roger adds that efruxifermin, an FGF21, has the potential to regress fibrosis in pre-cirrhotic patients. Ken notes it was previously thought that a monotherapy would cure NASH. Today, the promise of combination therapies demonstrates benefits which positively impact weight and other cardiometabolic variables. Roger echoes the idea that the ability to stop progression and reduce steatosis is an achievable target today.

23:14
Shifting to diagnostics, Roger explains the fading narrative of biopsy as a gold standard. Mazen emphasizes need to screen Type 2 diabetics and those with two or more metabolic risk factors. He introduces a simple test, called FIB-4, which helps to estimate the amount of scarring in the liver. FIB-4 is a basic computation that factors a patient’s age, liver enzymes and platelet count. He also describes transient elastography FibroScan, a noninvasive method evaluating liver fibrosis by measurement of liver stiffness. Lastly, he details the enhanced liver fibrosis (ELF) test, a blood test that provides a score reflecting the severity of liver fibrosis. A key message: patients with Stage 2 fibrosis and higher need to be referred as this is the population with significant risk of facing severe complications. Ken builds on the idea behind criticality in screening and identifying early in disease progression. There are simply not enough hepatologists to treat the millions of patients with liver disease.

34:17
After more notes around guidelines and practical, systemic approaches to navigate widespread prevalence, the panelists offer closing comments. The final points focus on: 1) biggest takeaways for frontline treaters, and 2) most exciting elements to emerge in this space in 2023.

As the Rising Tide series kicks off, we kindly ask you to share it and submit a review wherever you download our episodes. We also encourage our audience to write us questions and look forward to integrating your on-ground perspectives in the discourse.

This podcast series and all episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only and should not be taken as medical advice.

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

jump to episode >

S2-E3 – Why Clinical Care Pathways Matter

In this episode of the Rising Tide series, co-hosts Ken Cusi and Roger Green are joined by KOL in public health, Jeff Lazarus, and physician and associate professor of internal medicine, Jeff Budd. The panelists focus on why clinical care pathways matter and drive the message that primary care plays an integral role in fighting fatty liver.

jump to episode >

S2-E2 – A Deeper Dive Into Fatty Liver, NAFLD, and NASH

In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.

jump to episode >

S2-1 – Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline

In the Season 2 debut of the Rising Tide series for healthcare professionals who treat diabetic patients, the patients themselves and their caregivers, co-hosts Ken Cusi and Roger Green are joined by Mazen Noureddin to talk about prevalence and taking action on the frontlines today. The trio explore emerging NASH drugs, noninvasive testing and guidelines for treating different stages of disease progression.

jump to episode >

S1-E2 — What’s Behind The New AACE Fatty Liver Guidelines?

Drs. Mary Rinella, Zobair Younossi and Diana Barb join co-hosts Dr. Ken Cusi and Roger Green to explore the new AACE Fatty Liver guidelines. Learn about the epidemiology and research behind the guidelines and what they recommend for endocrinologists, primary care physicians and allied health professionals when screening, diagnosing and managing Type 2 Diabetes patients for Fatty Liver disease.

jump to episode >

S1-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that reported, in a prospective random sample of 835 people with a median age of 55, NAFLD prevalence as being 37%, NASH as being 14% and advanced fibrosis as being 6% in a random asymptomatic patients. Among patient with Type 2 Diabetes, NAFLD prevalence was 70% and NASH was 35%.

jump to episode >

S1-E1 – New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

In this Premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors Stephen Harrison, Kathleen Corey and Kay Pepin join co-hosts Dr. Ken Cusi and Roger Green to discuss key issues related to the NAFLD-Diabetes Link, NAFLD-Diabetes Dual Prevalence: very high NAFLD and NASH prevalence in diabetics leads to increased CVD risk and other metabolic issues.

jump to episode >

Welcome!

Welcome to the world's leading source for Fatty Liver podcasts, with close to 500 episodes and conversations with the world's leading Key Opinion Leaders. Listen, learn, participate.

One-Time Access Here

Register below for one-time access to this episode, or register to the lower right for full site access, tailored content alerts and information on fatty liver disease

or gain All-Access!

Skip this lite gate by registering for a tailored experience.
One log-in gives you access to all Diabetes episodes!